Comments
UBS has raised the target on Indian pharma stocks, but is has downgraded IPCA.
It has cited higher generic drug prices and brand inflation in United States and rolling over valuation to FY17’s earning estimates.
It says most investors appreciate improving cash generation by Indian pharmaceutical companies, especially the large-caps.
UBS’ new targets
For Cadila Healthcare, it has given buy rating with a new target price of Rs 2,135 against old target price of Rs 2,040.
For Cipla, the rating is neutral and the new target price is Rs 785 (Rs 725)
Dr.Reddy’s Laboratories has been given buy rating with a new target price of Rs 4,150 (Rs 4,000).
For Glenmark Pharmaceutical, it has given buy rating and the new target price is Rs 1,032 (Rs 900).
Lupin has buy rating and the new target price is Rs 2,315 (Rs 1,825).
Ranbaxy Laboratories — Buy — Rs 1,008 (Rs 880), Sun Pharmaceutical Industries — Buy — Rs 1,260 (Rs 1,100), and Torrent Pharmaceuticals — Buy — Rs 1,440 (Rs 1,425).
Also, UBS has downgraded IPCA Laboratories to “neutral’’ from “buy” but ‘has raised the target to Rs 860 from Rs 785.
Fund managers have started churning in favour of defensive stocks like pharmaceuticals, citing India’s weak earnings, outperformance and the Fed risk.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.